Autologous stem cell transplant program
The physicians, nurses, and professional team at Legacy Health have provided safe and effective autologous (meaning "from the self") transplant care for more than 20 years.
Accreditation and outcomes
In 2000, the autologous stem cell transplant program at Legacy Good Samaritan was nationally accredited by the Foundation of Cellular Therapy, or FACT. Since then we have consistently met the high standards necessary to maintain FACT accreditation. In addition, our program is a center of excellence for most major insurance companies.
Our patient outcomes are excellent, meeting or exceeding the results published by the national database of the Center for International Blood and Marrow Transplant Research. One-year survival rates exceed 90% and transplant-related mortality is less than 1%. Please see the 2008 Annual Report from Legacy Cancer Institute for more detail.
Autologous transplantation can offer potential long-term control or cure for patients with:
- Hodgkin's disease that has recurred or never entered complete remission
- Multiple myeloma after initial therapy to help provide the best remission. Also used in patients who have had the disease return as long as the myeloma is still responding well to treatment.
- Non-Hodgkin's lymphoma that has recurred or never entered complete remission. In certain high-risk lymphomas, autologous transplant may be done after initial treatment to reduce the chance that the lymphoma will return.
- Primary amyloidosis involving no more than 2 organs. Patients must have adequate heart function.
- Testicular/germ cell cancer that has recurred
To learn more about our program
Further Legacy resources